NICE knocks back advanced kidney cancer drug duo

While the guidance is only in its draft stage, the decision could mean that Eisai ’s Kisplyx (lenvatinib) and Eusa Pharma’s Fotivda (tivozanib) are withheld from NHS patients in England and Wales.08/15/2017
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news